Company intelligence / Profile preview

InCarda Therapeutics

San Francisco, California, United Statesincardatherapeutics.com ↗

Ownership: Private
Development stage: Phase 3

Overview

InCarda's lead product InRhythm (orally inhaled flecainide) has completed Phase 2 trials showing rapid conversion from atrial fibrillation to normal sinus rhythm with median conversion time of less than 15 minutes. The company started a pivotal Phase 3 RESTORE-1 trial but halted it according to recent information from September 2024. They are planning continued development with a new delivery system[6][7][10].

Therapeutic areas: Cardiovascular
Modalities: Inhaled therapiesspecifically inhaled flecainide
Industry: Biotech

Drug pipeline

1 asset

flecainide acetate inhalation solution

Unknown

Beyond the preview

Go deeper on InCarda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InCarda Therapeutics.

Explore the full profile